ArticleBlood advances2017
Targeted inhibition of the MAPK pathway: emerging salvage option for progressive life-threatening multisystem LCH.
Article in Blood advances, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 42 citations in OpenAlex.
- Long-term MAPK inhibition of childhood refractory-Langerhans cell histiocytosis: an observational study of 288 patients.Blood advances · 2026Observational
- BRAFV600E induces key features of LCH in iPSCs with cell type-specific phenotypes and drug responses.Blood · 2025Article
- Real-world experience with targeted therapy in patients with histiocytic neoplasms in the Netherlands and in Belgium.Blood neoplasia · 2024Article
- Liver transplantation in a child with sclerosing cholangitis due to Langerhans cell histiocytosis: a case report.Frontiers in pediatrics · 2024Article
- Treatment of Langerhans Cell Histiocytosis and Histiocytic Disorders: A Focus on MAPK Pathway Inhibitors.Paediatric drugs · 2023Review
- Signaling pathways, microenvironment, and targeted treatments in Langerhans cell histiocytosis.Cell communication and signaling : CCS · 2022Review
- Development of BRAFV600E-positive acute myeloid leukemia in a patient on long-term dabrafenib for multisystem LCH.Blood advances · 2022Article
- Vemurafenib acts as a molecular on-off switch governing systemic inflammation in Langerhans cell histiocytosis.Blood advances · 2022Article
- Response to mitogen-activated protein kinase inhibition of neurodegeneration in Langerhans cell histiocytosis monitored by cerebrospinal fluid neurofilament light as a biomarker: a pilot study.British journal of haematology · 2022Article
- Recent advances in the understanding of the molecular pathogenesis and targeted therapy options in Langerhans cell histiocytosis.Blood research · 2021Review
- Case Report: Early Association of Vemurafenib to Standard Chemotherapy in Multisystem Langerhans Cell Histiocytosis in a Newborn: Taking a Chance for a Better Outcome?Frontiers in oncology · 2021Article
- Immune Microenvironment in Langerhans Cell Histiocytosis: Potential Prognostic Indicators.Frontiers in oncology · 2021Article
- High-risk LCH in infants is serially transplantable in a xenograft model but responds durably to targeted therapy.Blood advances · 2020Article
- Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019Observational
- Article
- Longitudinal assessment of peripheral blood BRAFV600E levels in patients with Langerhans cell histiocytosis.Pediatric research · 2019Article
- Clinical responses and persistentBlood · 2019Article
- Vemurafenib in Langerhans cell histiocytosis: report of a pediatric patient and review of the literature.Oncotarget · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Single-agent vemurafenib leads to a rapid and sustained clinical response in severe multisystem LCH but does not eradicate the disease.Longitudinal assessment of
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.